BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 27492699)

  • 1. PT, aPTT, TT and the hemostatic safety threshold of dabigatran and rivaroxaban.
    Ibrahim F; Calmette L; Layka A; Horellou MH; Mazoyer É; Gouin-Thibault I; Flaujac C
    Ann Biol Clin (Paris); 2016 Aug; 74(4):457-64. PubMed ID: 27492699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013.
    Pernod G; Albaladejo P; Godier A; Samama CM; Susen S; Gruel Y; Blais N; Fontana P; Cohen A; Llau JV; Rosencher N; Schved JF; de Maistre E; Samama MM; Mismetti P; Sié P;
    Arch Cardiovasc Dis; 2013; 106(6-7):382-93. PubMed ID: 23810130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study.
    Testa S; Legnani C; Tripodi A; Paoletti O; Pengo V; Abbate R; Bassi L; Carraro P; Cini M; Paniccia R; Poli D; Palareti G
    J Thromb Haemost; 2016 Nov; 14(11):2194-2201. PubMed ID: 27566988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emergency Coagulation Assessment During Treatment With Direct Oral Anticoagulants: Limitations and Solutions.
    Ebner M; Birschmann I; Peter A; Härtig F; Spencer C; Kuhn J; Blumenstock G; Zuern CS; Ziemann U; Poli S
    Stroke; 2017 Sep; 48(9):2457-2463. PubMed ID: 28775134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Point-of-care coagulation testing for assessment of the pharmacodynamic anticoagulant effect of direct oral anticoagulant.
    Mani H; Herth N; Kasper A; Wendt T; Schuettfort G; Weil Y; Pfeilschifter W; Linnemann B; Herrmann E; Lindhoff-Last E
    Ther Drug Monit; 2014 Oct; 36(5):624-31. PubMed ID: 24577124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interlaboratory variability in the measurement of direct oral anticoagulants: results from the external quality assessment scheme.
    Tripodi A; Chantarangkul V; Legnani C; Testa S; Tosetto A
    J Thromb Haemost; 2018 Mar; 16(3):565-570. PubMed ID: 29322630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of direct oral anticoagulants on lupus anticoagulant assays in a real-life setting.
    Antovic A; Norberg EM; Berndtsson M; Rasmuson A; Malmström RE; Skeppholm M; Antovic J
    Thromb Haemost; 2017 Aug; 117(9):1700-1704. PubMed ID: 28640321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peri-procedural management of dabigatran and rivaroxaban: Duration of anticoagulant discontinuation and drug concentrations.
    Godier A; Martin AC; Leblanc I; Mazoyer E; Horellou MH; Ibrahim F; Flaujac C; Golmard JL; Rosencher N; Gouin-Thibault I
    Thromb Res; 2015 Oct; 136(4):763-8. PubMed ID: 26319422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of dabigatran and rivaroxaban by ultra-performance liquid chromatography-tandem mass spectrometry and coagulation assays after major orthopaedic surgery.
    Schellings MW; Boonen K; Schmitz EM; Jonkers F; van den Heuvel DJ; Besselaar A; Hendriks JG; van de Kerkhof D
    Thromb Res; 2016 Mar; 139():128-34. PubMed ID: 26916310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants.
    Ebner M; Birschmann I; Peter A; Spencer C; Härtig F; Kuhn J; Blumenstock G; Zuern CS; Ziemann U; Poli S
    Crit Care; 2017 Feb; 21(1):32. PubMed ID: 28196509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitivity of routine coagulation assays to direct oral anticoagulants: patient samples versus commercial drug-specific calibrators.
    Lim MS; Chapman K; Swanepoel P; Enjeti AK
    Pathology; 2016 Dec; 48(7):712-719. PubMed ID: 27780603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coagulation Factor Concentrates Fail to Restore Alterations in Fibrin Formation Caused by Rivaroxaban or Dabigatran in Studies With Flowing Blood From Treated Healthy Volunteers.
    Arellano-Rodrigo E; Lopez-Vilchez I; Galan AM; Molina P; Reverter JC; Carné X; Villalta J; Tassies D; Lozano M; Díaz-Ricart M; Escolar G
    Transfus Med Rev; 2015 Oct; 29(4):242-9. PubMed ID: 26364029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of dabigatran, rivaroxaban and apixaban target-specific assays in a multicenter French study.
    Gouin-Thibault I; Freyburger G; de Maistre E; Susen S; Delavenne X; Golmard JL; Gruel Y; Sié P;
    Thromb Res; 2017 Oct; 158():126-133. PubMed ID: 28892657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of dabigatran and rivaroxaban on routine coagulation assays. A nationwide Belgian survey.
    Van Blerk M; Bailleul E; Chatelain B; Demulder A; Devreese K; Douxfils J; Jochmans K; Mullier F; Wijns W; Soumali MR; Coucke W; Vernelen K; Van de Walle P
    Thromb Haemost; 2015 Jan; 113(1):154-64. PubMed ID: 25231101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct oral anticoagulants and heparins: laboratory values and pitfalls in 'bridging therapy'.
    Eller T; Flieder T; Fox V; Gripp T; Dittrich M; Kuhn J; Alban S; Knabbe C; Birschmann I
    Eur J Cardiothorac Surg; 2017 Apr; 51(4):624-632. PubMed ID: 28043992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microfluidic coagulation assay for monitoring anticoagulant therapy in acute stroke patients.
    Bluecher A; Meyer Dos Santos S; Ferreirós N; Labocha S; Meyer Dos Santos IM; Picard-Willems B; Harder S; Singer OC
    Thromb Haemost; 2017 Feb; 117(3):519-528. PubMed ID: 28124061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multianalyte Determination of NOACs Using LC-MS/MS and Comparison with Functional Coagulation Assays.
    Slavik L; Lukes J; Friedecky D; Zhanelova M; Nemcova M; Ulehlova J; Prochazkova J; Hlusi A; Palova M; Vaclavik J
    Clin Lab; 2018 Oct; 64(10):1611-1621. PubMed ID: 30336535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Routine Coagulation Tests in Patients With Nonvalvular Atrial Fibrillation Under Dabigatran and Rivaroxaban Therapy: An Affordable and Reliable Strategy?
    Silva VM; Scanavacca M; Darrieux F; Cavalheiro C; Strunz CC
    Clin Appl Thromb Hemost; 2019; 25():1076029619835053. PubMed ID: 30907118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interlaboratory Performance in Measurement of Dabigatran and Rivaroxaban.
    Volod O; Rollins-Raval M; Goodwin AJ; Higgins RA; Long T; Chandler WL; Harris NS; Pham HP; Isom JA; Moser K; Olson JD; Smock KJ; VanSandt A; Wool G; Chen D
    Arch Pathol Lab Med; 2022 Jan; 146(2):145-153. PubMed ID: 34133726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Practical Guide to Ordering and Interpreting Coagulation Tests for Patients on Direct Oral Anticoagulants in Singapore.
    Wong WH; Yip CY; Sum CL; Tan CW; Lee LH; Yap ES; Kuperan P; Ting WC; Ng HJ
    Ann Acad Med Singap; 2016 Mar; 45(3):98-105. PubMed ID: 27146462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.